Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
Vaccine skeptics have said changes were introduced to "accommodate" the shortcomings of the COVID-19 vaccines.
Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and ...
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...
Since COVID was first reported in December 2019, there have been more than 775 million recorded infections and more than 7 ...
Last year only 23% of Americans got an updated COVID-19 vaccine, according to the CDC. They recommend those six months and ...
In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season ...
The fall virus season is upon us, and the U.S. Food & Drug Administration just approved one of the newest tools to protect ...
New COVID-19 vaccines reached about 395,000 New Yorkers, or 3.5%, so far in fall 2024, as health officials push to reverse a trend of limited uptake of the shots despite their proven effectiveness at ...
COVID-19 and flu vaccination campaign is expected to start within days but the Department of Health has yet to announce its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback